Format

Send to

Choose Destination
Clin Chim Acta. 2017 Feb;465:22-29. doi: 10.1016/j.cca.2016.12.006. Epub 2016 Dec 9.

Lipoprotein-associated phospholipase A2 in coronary heart disease: Review and meta-analysis.

Author information

1
Department of Emergency Medicine, West China Hospital, Sichuan University, Chengdu, China.
2
Department of Cardiology, Second Affiliated Hospital of Southwest Medical University, Luzhou, China.
3
Department of Cardiology, West China Hospital, Sichuan University, Chengdu, China.
4
Department of Pharmacology, Harbin Medical University, Harbin, China.
5
Department of Emergency Medicine, First Affiliated Hospital of Southwest Medical University, Luzhou, China.
6
Department of Cardiology, First Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
7
West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. Electronic address: zzw2002400@126.com.
8
West China School of Preclinical and Forensic Medicine, Sichuan University, Chengdu, China. Electronic address: jw@scu.edu.cn.

Abstract

BACKGROUND:

Risk associations between lipoprotein-associated phospholipase A2 (Lp-PLA2) and adverse outcomes in patients with coronary heart disease (CHD) remain unclear. The aim of the meta-analysis was to investigate the association between Lp-PLA2 and prognosis of CHD.

METHODS:

PubMed and Embase were examined for prospective studies published before June 2016. Multivariate-adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) for the risk of adverse outcomes according to Lp-PLA2 activity or mass were extracted, pooled, and weighted using generic inverse-variance and random-effect modeling.

RESULTS:

Fifteen studies with 30,857 participants were included. Overall, higher Lp-PLA2 activity or mass was not significantly related to increased risk of long-term all-cause mortality. However, higher Lp-PLA2 activity or mass was independently associated with an increased risk of long-term cardiovascular events, with pooled HR for cardiovascular events of 1.55 (95% CI, 1.08-2.23; P=0.018) and 1.62 (95% CI, 1.09-2.41; P=0.017), respectively. The prognostic value of Lp-PLA2 in predicting cardiovascular events was observed in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.

CONCLUSIONS:

Greater Lp-PLA2 activity or mass was independently associated with cardiovascular events in patients with CHD, particularly in patients with stable CHD who were not receiving therapies for inhibiting Lp-PLA2.

KEYWORDS:

Cardiovascular events; Coronary heart disease; Lipoprotein-associated phospholipase A2; Meta-analysis; Mortality

PMID:
27956130
DOI:
10.1016/j.cca.2016.12.006
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center